Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.69 |
| ▸ | LMNA | P02545 | 2/20 | 0.69 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.69 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.69 |
| ▸ | DHODH | Q02127 | 9/20 | 0.69 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.61 |
| ▸ | TP53 | P04637 | 1/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.61 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.61 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.61 |
| ▸ | POLB | P06746 | 1/20 | 0.58 |
| ▸ | GAA | P10253 | 1/20 | 0.58 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.56 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.56 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4248547 | 0.90 | KDM4E (0.72) | KDM4ELMNASMN1; SMN2PDE10ADHODH | |
| SCHEMBL15905102 | 0.87 | EPRS1 (0.64) | DHODHALDH1A1GAA | |
| SCHEMBL4247643 | 0.87 | ALDH1A1 (0.66) | KDM4ELMNASMN1; SMN2PDE10ADHODH | |
| SCHEMBL4248489 | 0.87 | DHODH (0.64) | KDM4ELMNASMN1; SMN2PDE10ADHODH | |
| SCHEMBL4252230 | 0.87 | ALDH1A1 (0.69) | KDM4ELMNASMN1; SMN2PDE10ADHODH | |
| SCHEMBL4248571 | 0.86 | KDM4E (0.60) | KDM4ELMNASMN1; SMN2PDE10ADHODH | |
| SCHEMBL4248498 | 0.86 | ALDH1A1 (0.54) | KDM4ELMNASMN1; SMN2PDE10ADHODH | |
| SCHEMBL4254130 | 0.86 | ALDH1A1 (0.61) | KDM4ELMNASMN1; SMN2PDE10ADHODH | |
| SCHEMBL4245149 | 0.85 | KDM4E (0.64) | KDM4ELMNASMN1; SMN2PDE10ADHODH | |
| SCHEMBL4255361 | 0.84 | DHODH (0.61) | KDM4ELMNASMN1; SMN2PDE10ADHODH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090042928-A1 | Modulators of muscarinic receptors | VERTEX PHARMACEUTICALS INCORPORATED | 2009-02-12 | — | — | US | disclosed |
| US-20090042928-A1 | Modulators of muscarinic receptors | VERTEX PHARMACEUTICALS INCORPORATED | 2009-02-12 | — | — | US | disclosed |
| US-20090042928-A1 | Modulators of muscarinic receptors | VERTEX PHARMACEUTICALS INCORPORATED | 2009-02-12 | — | — | US | disclosed |
| US-7446112-B2 | Modulators of muscarinic receptors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-11-04 | — | — | US | disclosed |
| US-7446112-B2 | Modulators of muscarinic receptors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-11-04 | — | — | US | disclosed |
| US-7446112-B2 | Modulators of muscarinic receptors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-11-04 | — | — | US | disclosed |
| EP-1709045-A1 | NAPHTHYRIDINE DERIVATIVES AND THEIR USE AS MODULATORS OF MUSCARINIC RECEPTORS | Vertex Pharmaceuticals Incorporated (US) | 2006-10-11 | — | — | EP | disclosed |
| US-20060142324-A1 | Aryl fused 2,4-disubstituted pyridines: NK3 receptor ligands | NEUROGEN CORPORATION | 2006-06-29 | — | — | US | disclosed |
| US-7037922-B1 | Aryl fused 2,4-disubstituted pyridines: NK3 receptor ligands | NEUROGEN CORPORATION (US) | 2006-05-02 | — | — | US | disclosed |
| US-20050171141-A1 | Modulators of muscarinic receptors | VERTEX PHARMACEUTICALS INCORPORATED | 2005-08-04 | — | — | US | disclosed |
| WO-2005056552-A1 | NAPHTHYRIDINE DERIVATIVES AND THEIR USE AS MODULATORS OF MUSCARINIC RECEPTORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2005-06-23 | — | — | WO | disclosed |
| WO-2005056552-A1 | NAPHTHYRIDINE DERIVATIVES AND THEIR USE AS MODULATORS OF MUSCARINIC RECEPTORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2005-06-23 | — | — | WO | disclosed |
| EP-1165555-B1 | ARYL FUSED 2,4-DISUBSTITUTED PYRIDINES: NK3 RECEPTOR LIGANDS | NEUROGEN CORP (US) | 2003-07-16 | — | — | EP | disclosed |
| EP-1165555-A2 | ARYL FUSED 2,4-DISUBSTITUTED PYRIDINES: NK3 RECEPTOR LIGANDS | NEUROGEN CORPORATION (US) | 2002-01-02 | — | — | EP | disclosed |
| WO-2000058307-A2 | ARYL FUSED 2,4-DISUBSTITUTED PYRIDINES: NK3 RECEPTOR LIGANDS | NEUROGEN CORPORATION (US) | 2000-10-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060142324-A1 | Aryl fused 2,4-disubstituted pyridines: NK3 receptor ligands | ACKR3, BDKRB1, GPR3 | KDM4E 1423/4885LMNA 3130/4885SMN1; SMN2 2509/4885 |
| US-20050171141-A1 | Modulators of muscarinic receptors | CHRM3, CHRM2, CHRM4 | KDM4E 4060/4885LMNA 4203/4885SMN1; SMN2 2267/4885 |
| US-20090042928-A1 | Modulators of muscarinic receptors | CHRM3, CHRM2, CHRM4 | KDM4E 4060/4885LMNA 4203/4885SMN1; SMN2 2267/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.